Plantar Fasciitis: What Could Be Causing It

How the Plantar Fascia Gets Injured

The plantar fascia is a dense, collagenous band that supports the medial longitudinal arch of the foot. Each step generates tension across this structure. When loading exceeds the tissue's capacity to repair, microtears develop at the calcaneal enthesis (the point where fascia attaches to the heel bone). This is where pain concentrates in most patients.

The term "fasciitis" implies inflammation, but histological studies show the process is predominantly degenerative rather than inflammatory. A 2003 analysis published in the Annals of Internal Medicine found that surgical specimens from chronic cases showed collagen disarray, angiofibroblastic changes, and an absence of inflammatory cells 1. This matters clinically because it explains why anti-inflammatory medications often provide only partial, temporary relief. The underlying problem is tissue degeneration from cumulative overload, not an acute inflammatory response.

Repetitive strain is dose-dependent. A runner adding 20% to weekly mileage, a warehouse worker standing 10 hours per shift on concrete, or a formerly sedentary person starting a walking program can each exceed the fascia's load tolerance. The tissue fails at its weakest point: the origin on the medial calcaneal tubercle.

Biomechanical Risk Factors

Foot structure and movement patterns are the strongest modifiable predictors of plantar fasciitis. Pes planus (flat feet) increases tension on the fascia by reducing arch support during midstance. Conversely, pes cavus (high arches) reduces the foot's ability to absorb shock, concentrating force at the heel.

A 2006 systematic review in the Journal of Foot and Ankle Research identified limited ankle dorsiflexion (tight calf muscles) as the single most consistent biomechanical risk factor across studies 2. When the gastrocnemius-soleus complex is tight, the foot compensates by pronating excessively at midfoot, transferring additional load onto the plantar fascia.

Other structural contributors include:

• Leg length discrepancy of more than 1 cm, which alters gait symmetry
• Excessive subtalar pronation, often visible as inward rolling of the ankle during walking
• First metatarsophalangeal joint stiffness, which disrupts the windlass mechanism that supports the arch during toe-off

These factors rarely act alone. A patient with tight calves, moderate overpronation, and a recent increase in walking volume has compounding risk. Clinical evaluation should assess all three domains: structure, flexibility, and recent loading history.

Obesity and Metabolic Factors

Body weight is a consistent, strong risk factor. A 2014 meta-analysis in Obesity Reviews pooled data from 10 studies (total N = 3,927) and found that individuals with a BMI above 30 had an odds ratio of 2.9 for developing plantar fasciitis compared to normal-weight controls 3. Each kilogram of body weight generates roughly 2 to 3 kg of force across the plantar fascia during walking.

The relationship extends beyond mechanical loading. Adipose tissue is metabolically active, producing systemic cytokines (including IL-6 and TNF-alpha) that may impair tendon and fascia healing. A 2019 study in Diabetes Care reported that patients with type 2 diabetes had a 2.2-fold higher prevalence of plantar fasciopathy compared to age-matched controls without diabetes, independent of BMI 4. Glycation of collagen fibers reduces tissue elasticity, making the fascia more vulnerable to microtearing under normal loads.

For patients on GLP-1 receptor agonists such as semaglutide or tirzepatide, weight loss may reduce plantar fascia loading both mechanically and metabolically. No published trial has directly measured plantar fasciitis outcomes with GLP-1 therapy, but a 15% body weight reduction (as seen in SURMOUNT-1, N = 2,539) 5 would meaningfully decrease ground reaction forces through the heel. Clinicians should monitor foot pain as a secondary outcome in patients undergoing pharmacologic weight loss.

Occupational and Activity-Related Causes

Prolonged standing is one of the most underappreciated risk factors. A 2015 cross-sectional study in Occupational Medicine found that workers who stood for more than 8 hours per day had a 3.6-fold increased risk of plantar heel pain compared to those standing fewer than 4 hours 6. Factory workers, nurses, teachers, and retail employees are disproportionately affected.

Running accounts for a large share of activity-related cases. The incidence among recreational runners ranges from 4.5% to 10% annually, with risk concentrated in those who increase mileage or intensity too quickly 7. Hard or uneven running surfaces amplify the problem. Track athletes who transition from soft indoor surfaces to concrete also experience spikes in incidence.

Footwear plays a modifying role. Shoes with minimal arch support, worn-out midsoles, or inadequate heel cushioning fail to distribute load effectively. The American Academy of Orthopaedic Surgeons recommends replacing athletic shoes every 400 to 500 miles or every 6 months of regular use, whichever comes first 8.

A common clinical pattern: a sedentary patient adopts a new exercise routine (often walking or running) while wearing old shoes, and develops heel pain within 4 to 8 weeks. The fascia was deconditioned, the footwear was inadequate, and the load increase was too rapid. All three factors converged.

Age-Related and Hormonal Contributors

Plantar fasciitis peaks between ages 40 and 60. This coincides with age-related thinning of the heel fat pad, reduced collagen turnover in connective tissues, and declining tissue elasticity. The calcaneal fat pad, which serves as the foot's primary shock absorber, loses approximately 1 mm of thickness per decade after age 40 9.

Hormonal changes also contribute. Postmenopausal women have a higher incidence of plantar fasciopathy than premenopausal women of the same age range. Estrogen receptors are present in tendon and ligament tissue, and declining estrogen levels reduce collagen synthesis and tissue hydration. A 2020 retrospective cohort study in Menopause (N = 8,214) found that postmenopausal women not receiving hormone replacement therapy had a 1.7-fold higher risk of plantar fasciopathy compared to those on HRT 10.

This intersection of hormonal status and musculoskeletal health is clinically relevant for women in perimenopause or early postmenopause who develop new-onset heel pain. Musculoskeletal symptoms are frequently attributed to aging alone, when hormonal factors may be treatable.

Differential Diagnosis: When It Is Not Plantar Fasciitis

Not all heel pain is plantar fasciitis. Misdiagnosis delays appropriate treatment and can lead to unnecessary interventions. The American College of Foot and Ankle Surgeons identifies several conditions that mimic plantar fasciopathy 11.

Calcaneal stress fracture presents with diffuse heel pain that worsens with activity and does not improve with rest over days. Unlike plantar fasciitis, pain occurs with lateral squeeze of the calcaneus (the "squeeze test"). MRI is the gold standard for diagnosis. Risk factors include osteoporosis, rapid increases in impact activity, and female athlete triad.

Tarsal tunnel syndrome involves compression of the posterior tibial nerve as it passes behind the medial malleolus. Patients report burning, tingling, or numbness along the plantar surface. Tinel's sign (tapping over the tarsal tunnel reproduces symptoms) is positive in about 60% of cases. Electrodiagnostic studies confirm the diagnosis.

Fat pad atrophy causes diffuse central heel pain rather than the medial-plantar pattern typical of plantar fasciitis. Pain is worse on hard surfaces and with thin-soled shoes. Ultrasound showing fat pad thickness below 12 mm supports the diagnosis.

Baxter's neuropathy (entrapment of the inferior calcaneal nerve) produces medial heel pain that can closely mimic plantar fasciitis. Pain may radiate laterally along the heel. MRI showing denervation changes in the abductor digiti minimi muscle distinguishes this from fasciopathy.

Insertional Achilles tendinopathy produces posterior heel pain, sometimes overlapping with plantar symptoms. Tenderness is at the Achilles insertion on the posterior calcaneus rather than the plantar-medial surface.

A focused clinical exam, including palpation of the medial calcaneal tubercle, assessment of pain character with first steps, and reproduction of symptoms with passive dorsiflexion of the toes (the windlass test), correctly identifies plantar fasciitis in most cases. Imaging is reserved for atypical presentations, treatment failures beyond 6 to 8 weeks, or suspicion of fracture.

Evidence-Based Treatment Approach

Conservative treatment resolves 80% to 90% of cases. The foundation includes three components: load management, stretching, and supportive footwear.

Stretching protocols have the strongest evidence base. A 2006 randomized trial (N = 101) published in the Journal of Bone and Joint Surgery found that plantar fascia-specific stretching (crossing the affected leg over the opposite knee and pulling the toes into dorsiflexion for 10 seconds, 10 repetitions, three times daily) produced a 52% improvement in pain scores at 8 weeks, compared to 22% with Achilles tendon stretching alone 12.

Orthotic devices redistribute plantar pressure. Prefabricated arch supports perform comparably to custom orthotics in most studies. A Cochrane review (2008) concluded that both types reduce pain at 3 months compared to sham insoles 13.

Corticosteroid injections provide short-term relief (2 to 4 weeks) but carry risks of fat pad atrophy and plantar fascia rupture (estimated at 2% to 6% per injection) 14. Ultrasound-guided injections have better accuracy and outcomes than landmark-guided techniques. Most guidelines recommend no more than three injections per year.

Extracorporeal shockwave therapy (ESWT) is supported for recalcitrant cases lasting more than 6 months. A 2017 meta-analysis in the British Journal of Sports Medicine pooling 16 RCTs (N = 1,189) found that ESWT reduced pain by a mean of 2.1 points on a 10-point VAS compared to placebo 15.

Platelet-rich plasma (PRP) injections show promise in some trials but evidence remains mixed. A 2019 systematic review in Foot and Ankle International found PRP superior to corticosteroids at 6 months but not at 3 months 16.

Night splints, which hold the ankle in 5 degrees of dorsiflexion during sleep, reduce first-step morning pain by maintaining fascia length overnight. Compliance is the limiting factor: roughly 30% of patients discontinue use within 2 weeks due to discomfort.

When to Escalate Care

Most patients can be managed in primary care. Referral to a foot and ankle specialist is appropriate when:

• Pain persists beyond 6 months despite consistent conservative treatment
• Clinical examination suggests an alternative diagnosis (neuropathy, stress fracture)
• The patient has had a sudden increase in pain after an injection (possible fascia rupture)
• Bilateral symptoms in a young patient raise concern for systemic inflammatory arthropathy (seronegative spondyloarthropathy causes enthesitis that can mimic bilateral plantar fasciitis)

The American Academy of Family Physicians recommends imaging with ultrasound or MRI after 6 to 8 weeks of failed conservative therapy 17. Plantar fascia thickness above 4 mm on ultrasound supports the diagnosis, while MRI can identify bone marrow edema suggestive of stress fracture, or soft tissue changes indicating fat pad pathology.

Surgical intervention (partial plantar fasciotomy) is reserved for the 5% to 10% of cases that fail all conservative and procedural treatments after 12 months. A 2017 review in Foot and Ankle Clinics reported 70% to 90% satisfaction rates following open or endoscopic release, but recovery takes 6 to 10 weeks and arch collapse is a recognized long-term risk 18.